Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis

被引：0
|
作者：
Goldstein, Daniel A.
Chen, Qiushi
Ayer, Turgay
Chan, Kelvin K.
Virik, Kiran
Hammerman, Ariel
Brenner, Baruch
Flowers, Christopher
Hall, Peter
机构：
[1] Rabin Med Ctr, Davidoff Ctr, Petah Tiqwa, Israel
[2] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA
[3] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Tasmania, Dept Med, Hobart, Australia
[5] Clalit Hlth Serv Headquarters, Chief Physicians Off, Tel Aviv, Israel
[6] Rabin Med Ctr, Petah Tiqwa, Israel
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Edinburgh Canc Res Ctr, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6518
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K. W.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher R.
    Hall, Peter S.
    [J]. ONCOLOGIST, 2017, 22 (06): : 694 - 699
  • [2] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Capecitabine and bevacizumab (CB) maintenance treatment in metastatic colorectal cancer (mCRC): A cost-effectiveness analysis
    Franken, M.
    Van Rooijen, E.
    Van Tinteren, H.
    May, A.
    Mol, L.
    Ten Tije, A.
    Creemers, G. J.
    Van der Velden, A.
    Van der Torren, A.
    Uyl-de Groot, C.
    Punt, C.
    Koopman, M.
    Van Oijen, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S370
  • [4] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
    Sherman, Scott K.
    Lange, Joel J.
    Dahdaleh, Fadi S.
    Rajeev, Rahul
    Gamblin, T. Clark
    Polite, Blase N.
    Turaga, Kiran K.
    [J]. JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
  • [5] A cost-effectiveness analysis of pretreatment DPYD and UGT1A1 screening in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI plus bevacizumab (FOLFIRI plus Bev)
    Rivers, Zachary
    Stenehjem, David D.
    Jacobson, Pamala
    Lou, Emil
    Nelson, Andrew
    Kuntz, Karen M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC)
    Wong, Hui-Li
    Field, Kathryn Maree
    Lomax, Anna
    Tacey, Mark
    Shapiro, Jeremy David
    McKendrick, Joseph James
    Zlmet, Allan Solomon
    Yip, Desmond
    Nott, Louise M.
    Jennens, Ross
    Richardson, Gary Edward
    Tie, Jeanne
    Kosmider, Suzanne
    Parente, Phillip
    Lim, Lionel
    Cooray, Prasad
    Tran, Ben
    Desai, Jayesh
    Wong, Rachel
    Gibbs, Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan
    Shiroiwa, Takeru
    Fukuda, Takashi
    Tsutani, Kiichiro
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (10) : 2256 - 2267
  • [8] Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC).
    Lakdawalla, D.
    Penrod, J.
    Maclean, R.
    Humphrey, J. S.
    Seabury, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [9] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer
    Messori, Andrea
    De Rosa, Mauro
    Fadda, Valeria
    Pani, Luca
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3838 - +
12345